Car Halina, Bogucki Andrzej, Bonikowski Marcin, Dec-Ćwiek Małgorzata, Drużdż Artur, Koziorowski Dariusz, Rudzińska-Bar Monika, Sarzyńska-Długosz Iwona, Sławek Jarosław
Deprtment of Experimental Pharmacology, Medical University of Bialystok, Poland.
Department of Extrapyramidal Disorders, Medical University of Łódź, Poland.
Neurol Neurochir Pol. 2021;55(2):133-140. doi: 10.5603/PJNNS.a2021.0027. Epub 2021 Apr 2.
Botulinum neurotoxin type A (BoNT/A) formulations are widely used in clinical practice. Although they share a common mechanism of action resulting in presynaptic block in acetylocholine release, their structure and pharmacological properties demonstrate some similarities and many differences. Bioequivalence has been discussed since the onset of the clinical use of BoNT/A. In this review, we provide an update on the studies and compare the molecular structure, mechanisms of action, diffusion and spread, as well as immunogenicity and dose equivalence of onabotulinumtoxinA, abobotulinumtoxinA and incobotulinumtoxinA.
A型肉毒杆菌神经毒素（BoNT/A）制剂在临床实践中广泛应用。尽管它们具有共同的作用机制，导致乙酰胆碱释放的突触前阻滞，但其结构和药理特性既有一些相似之处，也存在许多差异。自BoNT/A临床应用伊始，生物等效性就一直被讨论。在本综述中，我们提供了相关研究的最新情况，并比较了A型肉毒毒素（onabotulinumtoxinA）、阿毒素（abobotulinumtoxinA）和因卡毒素（incobotulinumtoxinA）的分子结构、作用机制、扩散和传播，以及免疫原性和剂量等效性。
